What happened. On September 22, 2025, Omnicare (CVS Health’s long-term-care (LTC) pharmacy unit) filed for Chapter 11 following a July federal court judgment totaling $948.8M in False Claims Act (FCA) penalties and damages for billing government programs on invalid prescriptions (2010–2018). CVS says it will appeal. Omnicare obtained $110M in DIP financing to continue operations during the case and is exploring sale/restructuring options.
How we got here. After a 2015 whistleblower filing by former pharmacist Uri Bassan (the U.S. intervened in 2019), a New York jury found 3.34 million false claims and $135.6M in actual damages; the court then imposed $542M in FCA penalties and trebled damages to $406.8M. The court also found CVS jointly liable for $164.8M of penalties for post-acquisition conduct.
Why bankruptcy: Chapter 11 is used to stabilize operations, address the judgment, and potentially explore a sale or restructuring; Omnicare lined up $110 million in DIP financing to fund operations through the case.
Who Should Be Concerned: The Ripple Effects Across Healthcare
This case creates immediate compliance risks for multiple healthcare sectors:
Long-Term Care (LTC) Pharmacies: Pharmacies serving LTC facilities face increased scrutiny over prescription validation, billing, and integrated dispensing models, which mirror the violations in the case.
Pharmacy Benefit Managers (PBMs): PBMs must reassess claims validation systems to ensure automated processes can detect and flag potentially invalid prescriptions before reimbursement.
LTC Facilities and Operators: Facilities working with integrated pharmacy providers will face closer review of prescribing practices and medication management documentation.
Healthcare Acquirers: Buyers of healthcare entities must perform enhanced compliance due diligence and be ready for immediate post-closing remediation.
Understanding the Legal Landscape
The court's decision demonstrates several critical legal principles that every pharmacy serving government program beneficiaries must understand:
“Stale prescription” risk. Practices permitted by some state pharmacy laws can still violate federal billing rules for Medicare/Medicaid when a prescription has expired/invalid, creating FCA exposure once claims are submitted.
Corporate knowledge & willful blindness. The court emphasized repeated internal and regulatory warnings. Failure to act after notice results in dramatically increased penalties.
Parent-company liability. The court found CVS liable for causing false claims post-acquisition. Acquirers can face exposure even when the subsidiary submits the claims.
What Healthcare Entities Must Do Now
(a) Audit High-Risk Areas: Strengthen internal reviews of prescription validity, billing accuracy, and documentation, using statistical sampling to identify systemic issues.
(b) Segment Compliance Reviews: Maintain separate processes for state pharmacy laws and federal billing rules, with conflict escalation protocols.
(c) Establish Rapid Response Protocols: Create clear channels for escalating internal and external compliance concerns and respond swiftly to avoid enhanced penalties.
(d) Enhance M&A Diligence: Conduct FCA-specific due diligence during acquisitions and implement immediate compliance remediation post-closing.
(e) Prepare for Heightened Scrutiny: Expect intensified DOJ focus on LTC pharmacies, high-volume dispensing operations, and integrated care models in the wake of Omnicare.
Omnicare’s bankruptcy highlights how FCA violations, particularly around prescription validity and documentation, can escalate into existential threats. Heightened scrutiny across the LTC pharmacy landscape is imminent. The message is clear: proactive compliance is non-negotiable. Organizations must enforce strong internal controls, maintain audit-ready records, and respond swiftly under legal counsel. Seemingly minor technical lapses, when systemic, can trigger nine-figure liability.
Don’t wait for regulators - initiate targeted audits, reinforce compliance systems, and ensure board-level oversight. The success of Uri Bassan’s whistleblower claim will likely prompt increased internal scrutiny across the industry.
Please do not hesitate to reach out to our team at (212) 668-0200 or via email at info@mdrxlaw.com for a confidential consultation if you have questions or require consultation on any pharmacy-related topics.
